Nathaniel J Henning
Overview
Explore the profile of Nathaniel J Henning including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henning N, Manford A, Spradlin J, Brittain S, Zhang E, McKenna J, et al.
J Am Chem Soc
. 2023 Sep;
145(38):21142.
PMID: 37708357
No abstract available.
2.
Moon P, Zammit C, Shao Q, Dovala D, Boike L, Henning N, et al.
Chembiochem
. 2023 Apr;
24(11):e202300116.
PMID: 37069799
While vaccines and antivirals are now being deployed for the current SARS-CoV-2 pandemic, we require additional antiviral therapeutics to not only effectively combat SARS-CoV-2 and its variants, but also future...
3.
Du G, Jiang J, Henning N, Safaee N, Koide E, Nowak R, et al.
Cell Chem Biol
. 2022 Sep;
29(10):1470-1481.e31.
PMID: 36070758
Targeted protein degradation (TPD) uses small molecules to recruit E3 ubiquitin ligases into the proximity of proteins of interest, inducing ubiquitination-dependent degradation. A major bottleneck in the TPD field is...
4.
Boike L, Henning N, Nomura D
Nat Rev Drug Discov
. 2022 Aug;
21(12):881-898.
PMID: 36008483
Covalent drugs have been used to treat diseases for more than a century, but tools that facilitate the rational design of covalent drugs have emerged more recently. The purposeful addition...
5.
Henning N, Boike L, Spradlin J, Ward C, Liu G, Zhang E, et al.
Nat Chem Biol
. 2022 Feb;
18(4):412-421.
PMID: 35210618
Many diseases are driven by proteins that are aberrantly ubiquitinated and degraded. These diseases would be therapeutically benefited by targeted protein stabilization (TPS). Here we present deubiquitinase-targeting chimeras (DUBTACs), heterobifunctional...
6.
Henning N, Manford A, Spradlin J, Brittain S, Zhang E, McKenna J, et al.
J Am Chem Soc
. 2022 Jan;
144(2):701-708.
PMID: 34994556
Proteolysis-targeting chimeras (PROTACs), heterobifunctional compounds that consist of protein-targeting ligands linked to an E3 ligase recruiter, have arisen as a powerful therapeutic modality for targeted protein degradation (TPD). Despite the...
7.
Du G, Jiang J, Wu Q, Henning N, Donovan K, Yue H, et al.
Angew Chem Int Ed Engl
. 2021 Apr;
60(29):15905-15911.
PMID: 33915015
Aberrant activation of FGFR signaling occurs in many cancers, and ATP-competitive FGFR inhibitors have received regulatory approval. Despite demonstrating clinical efficacy, these inhibitors exhibit dose-limiting toxicity, potentially due to a...
8.
Shuster S, Fica-Contreras S, Hedges J, Henning N, Choi S
Biochem Biophys Res Commun
. 2020 Oct;
533(4):1298-1302.
PMID: 33046246
Reacted with methylglyoxal (MGO), murine Aβ(1-40) (mAβ) produced significantly less superoxide anion (O) compared to human Aβ (hAβ). The reactions of MGO with mAβ(R13H), hAβ(H13F), N-acetyl-l-lysine, and N-acetyl-l-arginine implied that...
9.
Boike L, Cioffi A, Majewski F, Co J, Henning N, Jones M, et al.
Cell Chem Biol
. 2020 Sep;
28(1):4-13.e17.
PMID: 32966806
MYC is a major oncogenic transcriptional driver of most human cancers that has remained intractable to direct targeting because much of MYC is intrinsically disordered. Here, we have performed a...
10.
Gurbani D, Du G, Henning N, Rao S, Bera A, Zhang T, et al.
Front Mol Biosci
. 2020 Jun;
7:81.
PMID: 32509799
Unregulated Src activity promotes malignant processes in cancer, but no Src-directed targeted therapies are used clinically, possibly because early Src inhibitors produce off-target effects leading to toxicity. Improved selective Src...